Bank of America Cuts Astrana Health (NASDAQ:ASTH) Price Target to $49.00

Astrana Health (NASDAQ:ASTH) had its price target reduced by Bank of America from $55.00 to $49.00 in a research report report published on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

Several other research firms have also recently commented on ASTH. Truist Financial lowered their target price on Astrana Health from $59.00 to $50.00 and set a “buy” rating for the company in a research note on Monday, January 13th. Stifel Nicolaus lowered their price objective on Astrana Health from $70.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, February 20th. Macquarie upgraded shares of Astrana Health to a “hold” rating in a research note on Monday, December 16th. Finally, Robert W. Baird decreased their price target on shares of Astrana Health from $86.00 to $50.00 and set an “outperform” rating for the company in a research note on Monday. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Astrana Health has a consensus rating of “Moderate Buy” and an average target price of $56.83.

Astrana Health Stock Up 0.1 %

Shares of ASTH opened at $27.21 on Tuesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. The stock has a market capitalization of $1.53 billion, a PE ratio of 20.93, a P/E/G ratio of 1.37 and a beta of 1.20. The company’s 50-day simple moving average is $34.44 and its 200-day simple moving average is $44.05. Astrana Health has a 1 year low of $23.12 and a 1 year high of $63.20.

Astrana Health (NASDAQ:ASTH) last released its earnings results on Thursday, February 27th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.37). The business had revenue of $665.21 million for the quarter, compared to analyst estimates of $617.24 million. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. Analysts forecast that Astrana Health will post 1.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Astrana Health

Several institutional investors have recently added to or reduced their stakes in ASTH. Janus Henderson Group PLC acquired a new stake in Astrana Health during the third quarter worth approximately $1,164,000. Royce & Associates LP purchased a new position in shares of Astrana Health in the 3rd quarter valued at $6,661,000. Amalgamated Bank acquired a new stake in Astrana Health during the 3rd quarter worth $713,000. Principal Financial Group Inc. purchased a new stake in Astrana Health in the third quarter valued at $13,383,000. Finally, Loomis Sayles & Co. L P acquired a new position in Astrana Health in the third quarter valued at $30,251,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.